Biotech - Spark Newswire

1 minute read

AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

Today, 5:30 PM

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating…

AZN

1 minute read

Merck’s Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting

By Vandana Singh

Today, 5:30 PM

Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment…

MRK

2 minute read

FDA
News

Virios Therapeutics Reports First Patient Dosed In P hase 2b Trial Evaluating IMC-1 In Patients with Fibromyalgia

By Benzinga Newsdesk

Today, 5:30 PM

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses,

VIRI

2 minute read

FDA
News

Imara To Present Clinical Data On IMR-687 In Sickle Cell Disease At European Hematology Association Congress Jun. 15 At 10 a.m. EDT

By Benzinga Newsdesk

Today, 5:30 PM

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m.

IMRA

1 minute read

FDA
News

Surface Oncology Reports Collaboration With Roche To Evaluate Co.’s Investigational Anti-IL-27 Antibody In Combo With Roche’s Atezolizumab, Bevacizumab In Patients With Treatment-Naïve Hepatocellular Carcinoma

By Benzinga Newsdesk

Today, 5:30 PM

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche

SURF

3 minute read

FDA
News

BeyondSpring Reports First Patient Dosed In Triple-Combo Study With Plinabulin, PD-1/PD-L1 Inhibitor, Radiotherapy For Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

By Benzinga Newsdesk

Today, 5:30 PM

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed

BYSI

6 minute read

FDA
News

Fate Therapeutics Reports Interim Data From Phase 1 Study Of FT516 In Combo With Rituximab For B-Cell Lymphoma At American Society Of Clinical Oncology

By Benzinga Newsdesk

Today, 5:30 PM

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable

FATE

3 minute read

FDA
News

AstraZeneca Reports IMFINZI Showed Survival In Unresectable Stage 3 Lung Cancer With 43% Of Patients Surviving 5 Years

By Benzinga Newsdesk

Today, 5:30 PM

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting WILMINGTON,

AZN